Skip to main content
TipRanks
Go Ultimate75% OFF

Royalty Pharma (RPD) AI Stock Analysis

6 Followers
DE:RPD

Royalty Pharma

(XETRA:RPD)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring receipt growthRising recurring royalty receipts and repeated guidance increases indicate durable demand across the underlying portfolio. This supports visibility into cash generation, strengthens funding capacity for new royalty acquisitions, and suggests growth is not dependent solely on occasional milestone payments.
Negative Factors
Meaningful leverageDebt provides acquisition capacity but creates a continuing claim on royalty cash flows through interest expense and principal obligations. Leverage can reduce flexibility if product receipts weaken or acquisition opportunities require additional funding, even with long debt duration and an undrawn revolver.

Royalty Pharma (RPD) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%100%DE:RPD+92.55%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 30.86B
Dividend Yield
1.36%
Average Volume (3M)
68
Price to Earnings (P/E)
41.0
Beta (1Y)
0.32
Revenue Growth
5.84%
EPS Growth
-16.96%
Country
Germany
Employees
100
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Royalty Pharma Business Overview & Revenue Model

Company Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...

Royalty Pharma Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:4.29%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

The call was strongly positive. Royalty Receipts and Portfolio Receipts grew 9% in the quarter, year-to-date Royalty Receipts grew 12%, returns remained attractive, guidance was raised for the third consecutive quarter, and the company reported substantial clinical, regulatory, pipeline, capital allocation, and business-development momentum. The principal negatives were the pelacarsen Phase III failure and $150 million noncash impairment, product declines in Promacta and Imbruvica, and lower expected milestone receipts, but management emphasized protective deal structures and continued portfolio growth.

Positive Updates

Strong Third-Quarter and Year-to-Date Receipt Growth
Portfolio Receipts and recurring Royalty Receipts each grew 9% in the third quarter. Royalty Receipts increased 12% year-to-date, while third-quarter Portfolio Receipts reached $890 million.

Negative Updates

Pelacarsen Phase III Failure and Impairment
Novartis' pelacarsen outcomes trial was unsuccessful, and Royalty Pharma recorded a $150 million noncash impairment charge. Management said it was disappointed by the result, although the related transaction was structured to protect the company's return.

Company Guidance

Royalty Pharma now expects 2026 Portfolio Receipts to be in the range of $3.5 billion to $3.55 billion, up from $3.4 billion to $3.5 billion previously, with growth in Royalty Receipts of around 10% to 11% compared with 7% to 10% previously; milestones and other contractual receipts are expected to decrease from $128 million in 2025 to approximately $65 million in 2026, operating and professional costs are expected to be in the range of 5.5% to 6% of portfolio receipts, and interest paid is expected to be around $350 million to $360 million, with interest paid anticipated to be a de minimis amount in Q4. The company expects to deploy around $2.5 billion per year over the long-term, deliver strong low volatility top and bottom line growth through 2030 and beyond, and generate an IRR and return on invested capital in the mid-teens and return on invested equity in the 20%-plus range; its development stage pipeline has the potential to add peak royalties of more than $1.7 billion, while Mimrylo has peak annual sales of between $1 billion and $2 billion and an expected unlevered IRR in the low double-digit percentage range, and Zoryve is expected to grow by more than 40% in 2026 to over $0.5 billion, with Arcutis’ peak sales estimate of $2.3 billion to $3 billion.

Royalty Pharma Risk Analysis

Royalty Pharma disclosed 58 risk factors in its most recent earnings report. Royalty Pharma reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Royalty Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:RPD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KNSAKNSA80Outperform$7.57B67.3617.27%―58.19%192.34%
CORTCORT72Outperform$7.98B48.6322.94%―30.02%48.80%
PBHPBH65Neutral$2.19B14.178.19%―5.10%-19.73%
LQDALQDA63Neutral$5.17B-55.74-116.64%―798.44%27.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SVASVA43Neutral$460.27M-7.79-0.94%―8.78%-227.47%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:RPDCORTPBHSVAKNSALQDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:RPD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:RPDRoyalty Pharma PLC62.3229.9192.26%
CORTCorcept Therapeutics72.94-2.18-2.90%
PBHPrestige Consumer Healthcare46.19-12.79-21.69%
SVASinovac Biotech6.470.000.00%
KNSAKiniksa Pharmaceuticals Ltd. Class A96.3354.93132.68%
LQDALiquidia Technologies57.4129.01102.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.